HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Shows Skin Authority Who’s Boss With Warning For Drug Claims

This article was originally published in The Rose Sheet

Executive Summary

Yet another skin-care marketer, Skin Authority, has been served with an FDA warning letter for excessive product claims that identify its offerings as drugs. The agency cites statements touting the firm’s ingredient benefits, including collagen production, improved circulation, inflammation relief and hyperpigmentation treatment, consistent with other warnings issued to cosmetics firms in recent months.

You may also be interested in...

FDA Warning Letter Recipients: Where Are Their Claims Now?

A key component of FDA’s enforcement strategy in the cosmetics space is monitoring companies’ websites for overreaching product claims and issuing warning letters accordingly. Examination of past offenders’ current sites and updated claims offers potential visibility into language the agency will and will not tolerate when it comes to promoting skin-care benefits.

FDA Warns Consumers About Skin-Whitening Injectables

A growing number of injectable skin-whitening products are available to consumers through online retailers and other channels, FDA says in an update cautioning the public that such products could pose "significant" safety risks. The agency singles out Flawless Beauty, LLC, which has been subject to recent enforcement activity, including product seizure by U.S. Marshals, but continues to market questionable skin-whitening products with aggressive claims.

NuGene Growing Its Stem-Cell Cosmeceuticals Biz; Regulatory Risks Noted

NuGene's sales have soared with expanded distribution, but increased regulation continues to be a risk to its human stem-cell-based cosmeceuticals business, the firm notes. Skin and hair-care line extensions will launch later this year, and the company is considering developing an in-house sales force.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts